We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 18, 2020

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced HCC Previously Treated With Sorafenib

JAMA Oncology

 

Additional Info

JAMA Oncology
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial
JAMA Oncol 2020 Oct 01;[EPub Ahead of Print], T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, M Kudo, MM Hou, A Matilla, F Tovoli, JJ Knox, A Ruth He, BF El-Rayes, M Acosta-Rivera, HY Lim, J Neely, Y Shen, T Wisniewski, J Anderson, C Hsu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading